{"id":4914,"date":"2026-04-20T14:52:02","date_gmt":"2026-04-20T14:52:02","guid":{"rendered":"https:\/\/vantagebiotrials.com\/?p=4914"},"modified":"2026-04-20T14:52:02","modified_gmt":"2026-04-20T14:52:02","slug":"vantage-biotrials-joins-canreview-partner-network-to-support-faster-clinical-trial-start-up-in-canada","status":"publish","type":"post","link":"https:\/\/vantagebiotrials.com\/fr\/vantage-biotrials-joins-canreview-partner-network-to-support-faster-clinical-trial-start-up-in-canada\/","title":{"rendered":"Vantage BioTrials Joins CanReview Partner Network to Support Faster Clinical Trial Start-Up in Canada"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-4915 aligncenter\" src=\"https:\/\/vantagebiotrials.com\/wp-content\/uploads\/2026\/04\/Logos_VBT_CanReview.jpg\" alt=\"\" width=\"503\" height=\"283\" srcset=\"https:\/\/vantagebiotrials.com\/wp-content\/uploads\/2026\/04\/Logos_VBT_CanReview.jpg 1280w, https:\/\/vantagebiotrials.com\/wp-content\/uploads\/2026\/04\/Logos_VBT_CanReview-18x10.jpg 18w, https:\/\/vantagebiotrials.com\/wp-content\/uploads\/2026\/04\/Logos_VBT_CanReview-600x338.jpg 600w\" sizes=\"(max-width: 503px) 100vw, 503px\" \/><\/p>\n<p>&nbsp;<\/p>\n<p><strong>April 20, 2026, Montr\u00e9al, Canada<\/strong> \u2013 Vantage BioTrials, a leading Canadian Contract Research Organization (CRO) specializing in clinical trial management services, is proud to support CanReview, a pan-Canadian collaboration supported by the Accelerating Clinical Trials (ACT) Consortium to build a broadly accessible, Canada-wide single research ethics review system that will enable all research sites participating in a multi-site clinical trial to undergo one ethics review, while ensuring the highest ethical standards.<\/p>\n<p>Collaborating with Research Ethics Boards, research teams, Indigenous community members, institutions and sponsors, patients and family partners, and many others, CanReview aims to enhance clinical trials efficiencies, increase Canada\u2019s competitiveness, expand clinical trials to underserved, rural and remote locations, and promote equitable access to trial participation.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Supporting Faster, More Coordinated Clinical Trial Activation in Canada<\/strong><\/p>\n<p>As a Canadian CRO specializing in full-service clinical trial management, Vantage BioTrials is aligned with national initiatives aimed at improving collaboration between sponsors, CROs, institutions and regulatory bodies.<\/p>\n<p>Through its participation in the CanReview partner network, Vantage BioTrials supports efforts to:<\/p>\n<ul>\n<li>Facilitate coordinated and harmonized REB submissions and approvals<\/li>\n<li>Enhance predictability in clinical trial start-up processes<\/li>\n<li>Strengthen Canada\u2019s position as a competitive destination for global clinical trials<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Aligned with Evolving Clinical Trial Regulatory and Operational Expectations<\/strong><\/p>\n<p>With increasing complexity in clinical development, early-stage coordination between stakeholders has become critical to minimizing delays and ensuring efficient trial execution.<\/p>\n<p>Since its founding in 2007, Vantage BioTrials has focused on delivering disciplined clinical trial management, incorporating:<\/p>\n<ul>\n<li>Proactive operational oversight<\/li>\n<li>Risk-based quality management strategies<\/li>\n<li>Transparent communication across stakeholders<\/li>\n<\/ul>\n<p>Participation in CanReview reflects the organization\u2019s continued commitment to working within the national Canadian clinical trial framework to support more efficient and coordinated study start-up.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Advancing Canada\u2019s Clinical Research Ecosystem<\/strong><\/p>\n<p>Canada continues to be recognized globally for its high-quality clinical research environment, strong regulatory framework and experienced clinical sites. Initiatives such as CanReview play an important role in ensuring that Canada remains competitive by improving the speed and coordination of trial activation.<\/p>\n<p>By aligning with these national efforts, Vantage BioTrials continues to support sponsors in navigating the Canadian clinical trial landscape with greater efficiency, predictability and operational excellence.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>About Vantage BioTrials<\/strong><\/p>\n<p>Vantage BioTrials is a Canadian-owned Contract Research Organization (CRO) that provides Phase I-IV clinical trial management services to the pharmaceutical, biotechnology and medical device industries. Known for its personalized service model, strategic value and commitment to quality, Vantage BioTrials uses innovative clinical trial management strategies focused on patient safety and the acceleration of new therapies to market. We offer a complete and integrated suite of full-service solutions designed to deliver operational efficiency at a competitive value across the life sciences sector.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>About CanReview<\/strong><\/p>\n<p>CanReview is a pan-Canadian collaboration supported by the Accelerating Clinical Trials (ACT) Consortium to enable single research ethics review for multi-site clinical trials conducted across Canada, while ensuring the highest ethical standards. Collaborating with Research Ethics Boards, research teams, Indigenous community members, institutions and sponsors, patients and family partners and others, we are developing a system to enhance efficiencies and increase Canada\u2019s competitiveness, expand clinical trials to underserved, rural and remote locations, and promote equitable access to trial participation. Together, we are building a Canada-wide ethics review system that benefits all people in Canada.<\/p>","protected":false},"excerpt":{"rendered":"<p>&nbsp; April 20, 2026, Montr\u00e9al, Canada \u2013 Vantage BioTrials, a leading Canadian Contract Research Organization (CRO) specializing in clinical trial management services, is proud to support CanReview, a pan-Canadian collaboration supported by the Accelerating Clinical Trials (ACT) Consortium to build a broadly accessible, Canada-wide single research ethics review system that will enable all research sites participating in a multi-site clinical trial to undergo one ethics review, while ensuring the highest ethical standards. Collaborating with Research Ethics Boards, research teams, Indigenous community members, institutions and sponsors, patients and family partners, and many others, CanReview aims to enhance clinical trials efficiencies, increase Canada\u2019s competitiveness, expand clinical trials to underserved, rural and remote locations, and promote equitable access to trial participation. &nbsp; Supporting Faster, More Coordinated Clinical Trial Activation in Canada As a Canadian CRO specializing in full-service clinical trial management, Vantage BioTrials is aligned with national initiatives aimed at improving collaboration between sponsors, CROs, institutions and regulatory bodies. Through its participation in the CanReview partner network, Vantage BioTrials supports efforts to: Facilitate coordinated and harmonized REB submissions and approvals Enhance predictability in clinical trial start-up processes Strengthen Canada\u2019s position as a competitive destination for global clinical trials &nbsp; Aligned with Evolving Clinical Trial Regulatory and Operational Expectations With increasing complexity in clinical development, early-stage coordination between stakeholders has become critical to minimizing delays and ensuring efficient trial execution. Since its founding in 2007, Vantage BioTrials has focused on delivering disciplined clinical trial management, incorporating: Proactive operational oversight Risk-based quality management strategies Transparent communication across stakeholders Participation in CanReview reflects the organization\u2019s continued commitment to working within the national Canadian clinical trial framework to support more efficient and coordinated study start-up. \u00a0 Advancing Canada\u2019s Clinical Research Ecosystem Canada continues to be recognized globally for its high-quality clinical research environment, strong regulatory framework and experienced clinical sites. Initiatives such as CanReview play an important role in ensuring that Canada remains competitive by improving the speed and coordination of trial activation. By aligning with these national efforts, Vantage BioTrials continues to support sponsors in navigating the Canadian clinical trial landscape with greater efficiency, predictability and operational excellence. &nbsp; About Vantage BioTrials Vantage BioTrials is a Canadian-owned Contract Research Organization (CRO) that provides Phase I-IV clinical trial management services to the pharmaceutical, biotechnology and medical device industries. Known for its personalized service model, strategic value and commitment to quality, Vantage BioTrials uses innovative clinical trial management strategies focused on patient safety and the acceleration of new therapies to market. We offer a complete and integrated suite of full-service solutions designed to deliver operational efficiency at a competitive value across the life sciences sector. &nbsp; About CanReview CanReview is a pan-Canadian collaboration supported by the Accelerating Clinical Trials (ACT) Consortium to enable single research ethics review for multi-site clinical trials conducted across Canada, while ensuring the highest ethical standards. Collaborating with Research Ethics Boards, research teams, Indigenous community members, institutions and sponsors, patients and family partners and others, we are developing a system to enhance efficiencies and increase Canada\u2019s competitiveness, expand clinical trials to underserved, rural and remote locations, and promote equitable access to trial participation. Together, we are building a Canada-wide ethics review system that benefits all people in Canada.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[18,20],"tags":[],"class_list":["post-4914","post","type-post","status-publish","format-standard","hentry","category-news-homepage","category-news-pressroom","cms-no-post-thumbnail"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/4914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/comments?post=4914"}],"version-history":[{"count":1,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/4914\/revisions"}],"predecessor-version":[{"id":4916,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/4914\/revisions\/4916"}],"wp:attachment":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/media?parent=4914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/categories?post=4914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/tags?post=4914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}